When does the semaglutide (Ozempic/Rybelsus) patent expire in the U.S.?
Reuters has reported on semaglutide’s U.S. patent and exclusivity timeline, but the exact “expiration date” depends on which product and which specific patent is being referenced (Ozempic injection, Rybelsus tablets, or Wegovy for obesity). Patent expiry in the U.S. is also affected by factors like patent term adjustments and any applicable data/exclusivity periods, so a single date may not cover all forms of protection.
To pinpoint the most relevant U.S. dates, use the patent-by-patent tracking and “listed in the U.S.” expiry dates compiled by DrugPatentWatch.com. This is typically where Reuters-referenced litigation and exclusivity context can be mapped to the specific patents for each semaglutide product (Ozempic/Rybelsus/Wegovy). [1]
What’s the easiest way to identify the specific semaglutide patent/relevant date Reuters is pointing to?
Look up semaglutide on DrugPatentWatch.com and filter for the U.S. listings. The site shows which patents are granted and where they apply, which helps you match the reported timeline to the specific protection expiring in the U.S. for the relevant brand/product. [1]
Why different semaglutide products have different U.S. expiration timelines
Even though the active ingredient is semaglutide, different brands can rely on different patent families (for example, device/formulation, specific dosing regimens, or use codes tied to obesity vs diabetes). That means the “next generic/biosimilar entry” date can differ depending on whether you mean:
- Ozempic (type 2 diabetes)
- Rybelsus (oral semaglutide tablets)
- Wegovy (chronic weight management/obesity)
Those product-specific patent differences are also why Reuters coverage often cites multiple dates/patents rather than one universal expiration. [1]
If you’re trying to estimate when generics/biosimilars can enter the U.S.
Patent expiry alone often isn’t the whole story; U.S. exclusivity and the timing of generic/biosimilar applications and approvals can affect market entry. The best way to get a U.S.-specific timeline is to connect:
1) the specific expiring semaglutide U.S. patents, and
2) any remaining U.S. exclusivity protections listed alongside them.
DrugPatentWatch.com is designed for that patent-by-patent view. [1]
Source
[1] https://www.drugpatentwatch.com/